Sutro Biopharma Inc Revenue Growth Rates (STRO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sutro Biopharma Inc   (NASDAQ: STRO)
 

STRO's Revenue Growth by Quarter and Year

Sutro Biopharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

STRO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 9.84
1st Quarter March 14.52
FY 24.36

STROs Annual Revenue
Sutro Biopharma Inc 's Revenue in the fiscal year 2025 $ 102.48 millions
Sutro Biopharma Inc 's Revenue in the fiscal year 2024 $ 62.04 millions
Sutro Biopharma Inc 's Revenue in the fiscal year 2023 $ 153.73 millions
Sutro Biopharma Inc 's Revenue in the fiscal year 2022 $ 67.77 millions
Sutro Biopharma Inc 's Revenue in the fiscal year 2021 $ 61.88 millions




STRO Revenue second quarter 2026 Y/Y Growth Comment
Sutro Biopharma Inc reported drop in Revenue in the second quarter 2026 by -84.57% to $ 9.84 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Sutro Biopharma Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 27.16%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue growth. While Sutro Biopharma Inc ' s Revenue meltdown of -84.57% ranks overall at the positon no. 302 in the second quarter 2026.


STRO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -21.34 % -86.98 % 1217.73 %
3rd Quarter September - 13.73 % -49.65 % -32.72 %
2nd Quarter June -84.57 % 147.96 % 146.97 % -62.95 %
1st Quarter March -16.55 % 33.74 % 2.68 % 114.75 %
FY   - 65.17 % -59.63 % -

Financial Statements
Sutro Biopharma Inc 's second quarter 2026 Revenue $ 9.84 millions STRO's Income Statement
Sutro Biopharma Inc 's second quarter 2025 Revenue $ 63.75 millions Quarterly STRO's Income Statement


STRO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 20.23 % 73.83 % 572.1 %
3rd Quarter September - -84.8 % -66.86 % 62.54 %
2nd Quarter June -32.24 % 266.38 % 97.62 % -17.84 %
1st Quarter March 24.64 % 17.49 % -88.56 % 46.81 %
FY (Year on Year)   - 65.17 % -59.63 % -


Back to STRO Growth rate Comparisons >> Back to STRO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #82
Overall #302

Revenue Y/Y Growth Statistics
High Average Low
230.9 % 27.16 % -59.64 %
(Sep 30 2024)   (Dec 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #82
Overall #302
Revenue Y/Y Growth Statistics
High Average Low
230.9 % 27.16 % -59.64 %
(Sep 30 2024)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sutro Biopharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
571.95 % 38.92 % -88.56 %
(Dec 31 2023)  


STRO's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Sutro Biopharma Inc disclosed fall in Revenue from the first quarter by -32.24% to $ 9.84 millions, from $ 14.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Sutro Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 3512.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #490
Overall #3512
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #49
Healthcare Sector #490
Overall #3512
Revenue Q/Q Growth Statistics
High Average Low
571.95 % 38.92 % -88.56 %
(Dec 31 2023)  


STRO's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Sutro Biopharma Inc disclosed fall in Revenue from the first quarter by -32.24% to $ 9.84 millions, from $ 14.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Sutro Biopharma Inc 's Revenue growth quarter on quarter, overall rank is 3512.


Sutro Biopharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 45.70 $ 99.61 $ 102.48 $ 105.65 $ 104.47
Y / Y Revenue Growth (TTM) -56.25 % 49.94 % 65.18 % -34.36 % -38.31 %
Year on Year Revenue Growth Overall Ranking # 3585 # 3063 # 3240 # 15 # 49
Seqeuential Revenue Change (TTM) -54.12 % -2.81 % -2.99 % 1.12 % 57.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 302 # 1525 # 3245 # 1247 # 1086


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Sutro Biopharma Inc reported a sharp drop in Revenue by -56.25% year on year, to $46 millions, compare to the 49.94% growth at Mar 31 2026.

In the Healthcare sector 484 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3063 to 3585.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 485
Overall # 3585

Revenue TTM Y/Y Growth Statistics
High Average Low
230.9 %
 27.16 %
-59.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 82
S&P 500 # 302
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Sutro Biopharma Inc reported a sharp drop in Revenue by -56.25% year on year, to $46 millions, compare to the 49.94% growth at Mar 31 2026.

In the Healthcare sector 484 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3063 to 3585.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 485
Overall # 3585

Revenue TTM Y/Y Growth Statistics
High Average Low
230.9 %
27.16 %
-59.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 82
S&P 500 # 302




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STRO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Sutro Biopharma Inc Revenue Growth Rates (STRO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sutro Biopharma Inc (CIK 1382101).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-345748
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sutro Biopharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.